Myelofibrosis with myeloid metaplasia

therapeutic options in 2003.

Ruben A. Mesa

Research output: Contribution to journalArticle

10 Citations (Scopus)

Abstract

Myelofibrosis with myeloid metaplasia (MMM) is a progressive, clonal, and lethal myeloproliferative disorder with a variable prognosis. The only potentially curative therapy for MMM is allogeneic stem cell transplantation, but this therapy is too toxic for older patients and inappropriate for young patients with good prognostic features. A nonmyeloablative or autologous stem cell transplant may broaden the applicability of high-dose therapy for MMM, but the therapy for MMM is palliative in intent and aimed at symptomatic relief. There is no approved therapy for MMM; however, certain agents have been useful for targeted palliation. Myelosuppressive drug therapy, targeted radiation, or splenectomy has decreased symptomatic myeloproliferation (i.e., splenomegaly). MMM-associated cytopenias may be improved by the selective use of growth factors, androgens, and thalidomide. Debilitating constitutional symptoms improve with the pharmacologic blockage of tumor necrosis factor-alpha. Further molecular understanding of MMM is necessary for more effective targeted therapies.

Original languageEnglish (US)
Pages (from-to)264-270
Number of pages7
JournalCurrent hematology reports
Volume2
Issue number3
StatePublished - May 2003

Fingerprint

Primary Myelofibrosis
Therapeutics
Myeloproliferative Disorders
Thalidomide
Poisons
Splenomegaly
Stem Cell Transplantation
Splenectomy
Cell- and Tissue-Based Therapy
Androgens
Intercellular Signaling Peptides and Proteins
Stem Cells
Tumor Necrosis Factor-alpha
Radiation
Transplants
Drug Therapy

ASJC Scopus subject areas

  • Hematology

Cite this

Myelofibrosis with myeloid metaplasia : therapeutic options in 2003. / Mesa, Ruben A.

In: Current hematology reports, Vol. 2, No. 3, 05.2003, p. 264-270.

Research output: Contribution to journalArticle

@article{b0ad58ae94de4fb68066585529472627,
title = "Myelofibrosis with myeloid metaplasia: therapeutic options in 2003.",
abstract = "Myelofibrosis with myeloid metaplasia (MMM) is a progressive, clonal, and lethal myeloproliferative disorder with a variable prognosis. The only potentially curative therapy for MMM is allogeneic stem cell transplantation, but this therapy is too toxic for older patients and inappropriate for young patients with good prognostic features. A nonmyeloablative or autologous stem cell transplant may broaden the applicability of high-dose therapy for MMM, but the therapy for MMM is palliative in intent and aimed at symptomatic relief. There is no approved therapy for MMM; however, certain agents have been useful for targeted palliation. Myelosuppressive drug therapy, targeted radiation, or splenectomy has decreased symptomatic myeloproliferation (i.e., splenomegaly). MMM-associated cytopenias may be improved by the selective use of growth factors, androgens, and thalidomide. Debilitating constitutional symptoms improve with the pharmacologic blockage of tumor necrosis factor-alpha. Further molecular understanding of MMM is necessary for more effective targeted therapies.",
author = "Mesa, {Ruben A.}",
year = "2003",
month = "5",
language = "English (US)",
volume = "2",
pages = "264--270",
journal = "Current hematology reports",
issn = "1540-3408",
publisher = "Current Science, Inc.",
number = "3",

}

TY - JOUR

T1 - Myelofibrosis with myeloid metaplasia

T2 - therapeutic options in 2003.

AU - Mesa, Ruben A.

PY - 2003/5

Y1 - 2003/5

N2 - Myelofibrosis with myeloid metaplasia (MMM) is a progressive, clonal, and lethal myeloproliferative disorder with a variable prognosis. The only potentially curative therapy for MMM is allogeneic stem cell transplantation, but this therapy is too toxic for older patients and inappropriate for young patients with good prognostic features. A nonmyeloablative or autologous stem cell transplant may broaden the applicability of high-dose therapy for MMM, but the therapy for MMM is palliative in intent and aimed at symptomatic relief. There is no approved therapy for MMM; however, certain agents have been useful for targeted palliation. Myelosuppressive drug therapy, targeted radiation, or splenectomy has decreased symptomatic myeloproliferation (i.e., splenomegaly). MMM-associated cytopenias may be improved by the selective use of growth factors, androgens, and thalidomide. Debilitating constitutional symptoms improve with the pharmacologic blockage of tumor necrosis factor-alpha. Further molecular understanding of MMM is necessary for more effective targeted therapies.

AB - Myelofibrosis with myeloid metaplasia (MMM) is a progressive, clonal, and lethal myeloproliferative disorder with a variable prognosis. The only potentially curative therapy for MMM is allogeneic stem cell transplantation, but this therapy is too toxic for older patients and inappropriate for young patients with good prognostic features. A nonmyeloablative or autologous stem cell transplant may broaden the applicability of high-dose therapy for MMM, but the therapy for MMM is palliative in intent and aimed at symptomatic relief. There is no approved therapy for MMM; however, certain agents have been useful for targeted palliation. Myelosuppressive drug therapy, targeted radiation, or splenectomy has decreased symptomatic myeloproliferation (i.e., splenomegaly). MMM-associated cytopenias may be improved by the selective use of growth factors, androgens, and thalidomide. Debilitating constitutional symptoms improve with the pharmacologic blockage of tumor necrosis factor-alpha. Further molecular understanding of MMM is necessary for more effective targeted therapies.

UR - http://www.scopus.com/inward/record.url?scp=0141921613&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0141921613&partnerID=8YFLogxK

M3 - Article

VL - 2

SP - 264

EP - 270

JO - Current hematology reports

JF - Current hematology reports

SN - 1540-3408

IS - 3

ER -